5 years ago

Cycle Pharmaceuticals Secures $25M Debt Financing from Deutsche Bank AG

  • Cycle Pharmaceuticals, a Cambridge, England-based biotechnology company specializing in rare disease treatments, has secured a $25 million debt financing facility from Deutsche Bank AG

  • This funding will support the company's efforts to expand its portfolio of rare disease treatments, including NITYR® (nitisinone) Tablets, which treats hereditary tyrosinemia type 1

  • The company's mission is to use the latest pharmaceutical technologies to deliver drug treatments to serve rare genetic disease patients.

      • ProblemHealthcare

      "Developing medicines for rare genetic metabolic diseases and neurological conditions to serve rare patient populations"

      Solution

      "Cycle Pharmaceuticals delivers drug treatments and services focused on rare genetic metabolic disorders and neurological conditions using latest pharmaceutical technologies"

      Covered on